{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03858153",
            "orgStudyIdInfo": {
                "id": "STUDY00003387"
            },
            "secondaryIdInfos": [
                {
                    "id": "K07CA221931",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/K07CA221931"
                }
            ],
            "organization": {
                "fullName": "University of Rochester",
                "class": "OTHER"
            },
            "briefTitle": "Exercise and Nutrition Interventions During Chemotherapy K07",
            "officialTitle": "The Effects of Exercise and Nutrition Interventions on Chemotherapy-induced Peripheral Neuropathy and Interoceptive Brain Circuitry",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "exercise-and-nutrition-interventions-during-chemotherapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-04-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-02-15",
            "studyFirstSubmitQcDate": "2019-02-26",
            "studyFirstPostDateStruct": {
                "date": "2019-02-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-10",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Po-Ju Lin",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "University of Rochester"
            },
            "leadSponsor": {
                "name": "University of Rochester",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of taxane chemotherapy, often used to treat breast cancer. Unfortunately there are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to inform a future study."
        },
        "conditionsModule": {
            "conditions": [
                "Neuropathy;Peripheral"
            ],
            "keywords": [
                "chemotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "maskingDescription": "Assessor and investigator will be masked of Arms to the extent possible (i.e., for some outcomes e.g., biomarkers but not others e.g. symptom tests).",
                    "whoMasked": [
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Exercise",
                    "type": "EXPERIMENTAL",
                    "description": "Exercise for Cancer Patients (EXCAP\u00a9\u00ae) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.",
                    "interventionNames": [
                        "Behavioral: EXCAP Exercise"
                    ]
                },
                {
                    "label": "Nutrition Education",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.",
                    "interventionNames": [
                        "Behavioral: Nutrition Education"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "EXCAP Exercise",
                    "description": "12 weeks of at-home walking and resistance exercise.",
                    "armGroupLabels": [
                        "Exercise"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Nutrition Education",
                    "description": "12 weeks of implementing eating tips and tracking food.",
                    "armGroupLabels": [
                        "Nutrition Education"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Patient-reported sensory symptoms of chemotherapy-induced peripheral neuropathy (CIPN)",
                    "description": "CIPN-20 sensory subscale (Postma et al 2005). The subscale includes 9 questions, each rated 1-4, and the score ranges from 9-36 with larger values reflecting more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).",
                    "timeFrame": "Time point 2 (approximately 6 weeks), controlling for baseline value"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Sensory loss",
                    "description": "Finger tactile sensitivity",
                    "timeFrame": "Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline"
                },
                {
                    "measure": "Numbness and tingling",
                    "description": "Patient-reported severity of numbness/tingling (0-10). A larger value reflects more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).",
                    "timeFrame": "Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline"
                },
                {
                    "measure": "Sensory, motor, and autonomic symptoms of CIPN",
                    "description": "CIPN-20 total score (Postma et al 2005). The score includes 20 questions, each rated 1-4, and the score ranges from 20-80 with larger values reflecting more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).",
                    "timeFrame": "Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks) or time point 4 (approx. 24 weeks), controlling for baseline"
                },
                {
                    "measure": "Patient-reported sensory symptoms of CIPN",
                    "description": "CIPN-20 sensory subscale (Postma et al 2005). The subscale includes 9 questions, each rated 1-4, and the score ranges from 9-36 with larger values reflecting more severe (worse) symptoms of chemotherapy-induced peripheral neuropathy (CIPN).",
                    "timeFrame": "Time point 3 (approx. 12 weeks) or time point 4 (approx. 25 weeks), controlling for baseline"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Musculoskeletal function",
                    "description": "Leg strength via isokinetic dynamometer test",
                    "timeFrame": "Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline"
                },
                {
                    "measure": "Cardiovascular function",
                    "description": "Distance walked in six-minute walk test",
                    "timeFrame": "Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline"
                },
                {
                    "measure": "Neuropsychological function",
                    "description": "Brain connectivity via functional magnetic resonance imaging",
                    "timeFrame": "Time point 2 (approx. 6 weeks), controlling for baseline"
                },
                {
                    "measure": "Immunological function",
                    "description": "Inflammatory cytokine concentration via ELISA (IL-6, IL-10, etc.)",
                    "timeFrame": "Time point 2 (approx. 6 weeks) or time point 3 (approx. 12 weeks), controlling for baseline"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria (subjects must...)\n\n1. Be female\n2. Have breast cancer\n3. Be scheduled to receive taxane chemotherapy without other neurotoxic chemotherapy (platinums, vinca alkaloids, bortezomib, thalidomide)\n4. Have at least six months life expectancy according to the patient's oncologist or designee\n5. Be able to read English\n6. Be at least 18 years old (no upper limit on age)\n7. Provide written informed consent\n\nExclusion criteria (subjects must not...)\n\n1. Be in the active or maintenance stage of exercise behavior (i.e., subjects must be sedentary)\n2. Have physical limitations (e.g., cardiorespiratory, orthopedic, central nervous system) that contraindicate participation in maximal physiological fitness testing and a low/moderate intensity home-based walking and progressive resistance exercise program.\n\nAdditional exclusion criteria only for patients performing the MRI scanning (40 of 80 enrolled subjects)\n\n1. Subjects must not have contraindications for MRI scanning (pacemaker, metal implants, pregnancy, chest expander from breast reconstruction, etc.-note that most port-a-caths are safe for MRI scanning)",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ian Kleckner, PhD, MPH",
                    "role": "CONTACT",
                    "phone": "410-706-5981",
                    "email": "ian.kleckner@umaryland.edu"
                },
                {
                    "name": "Po-Ju Lin, PhD, RD, MPH",
                    "role": "CONTACT",
                    "phone": "585-276-6001",
                    "email": "po-ju_lin@URMC.Rochester.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of Maryland",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ian Kleckner, PhD, MPH",
                            "role": "CONTACT",
                            "phone": "410-706-5981",
                            "email": "ian.kleckner@umaryland.edu"
                        },
                        {
                            "name": "Amelia Wagenknecht, BS",
                            "role": "CONTACT",
                            "phone": "410-706-6298",
                            "email": "awagenknecht@umaryland.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "University of Rochester Medical Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Rochester",
                    "state": "New York",
                    "zip": "14642",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.15478,
                        "lon": -77.61556
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "15911236",
                    "type": "BACKGROUND",
                    "citation": "Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R; EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005 May;41(8):1135-9. doi: 10.1016/j.ejca.2005.02.012. Epub 2005 Apr 14."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Interested researchers may contact the study PI with requests for collaboration."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010523",
                    "term": "Peripheral Nervous System Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13432",
                    "name": "Peripheral Nervous System Diseases",
                    "asFound": "Neuropathy;Peripheral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}